EP0077571A2 - Verfahren zur Herstellung einer Lymphokine - Google Patents
Verfahren zur Herstellung einer Lymphokine Download PDFInfo
- Publication number
- EP0077571A2 EP0077571A2 EP82109658A EP82109658A EP0077571A2 EP 0077571 A2 EP0077571 A2 EP 0077571A2 EP 82109658 A EP82109658 A EP 82109658A EP 82109658 A EP82109658 A EP 82109658A EP 0077571 A2 EP0077571 A2 EP 0077571A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- lymphokine
- cells
- culture
- hybridoma
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 210000004027 cell Anatomy 0.000 claims abstract description 132
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 40
- 239000012228 culture supernatant Substances 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 34
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 238000012258 culturing Methods 0.000 claims abstract description 16
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 13
- 102000008070 Interferon-gamma Human genes 0.000 claims abstract description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims abstract description 6
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 6
- 238000010367 cloning Methods 0.000 claims abstract description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims abstract description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 4
- 230000003213 activating effect Effects 0.000 claims abstract description 4
- 210000002540 macrophage Anatomy 0.000 claims abstract description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 116
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 6
- 238000005273 aeration Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 description 55
- 230000000694 effects Effects 0.000 description 35
- 102000008072 Lymphokines Human genes 0.000 description 19
- 108010074338 Lymphokines Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 230000003068 static effect Effects 0.000 description 17
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 16
- 208000008732 thymoma Diseases 0.000 description 14
- 210000004989 spleen cell Anatomy 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 8
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940104230 thymidine Drugs 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000011640 AKR mouse Methods 0.000 description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- 229960001005 tuberculin Drugs 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- XEQLGWAGMYUVTR-UHFFFAOYSA-N O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 XEQLGWAGMYUVTR-UHFFFAOYSA-N 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
Definitions
- TRF T lymphocyte replacing factor
- the thus obtained lymphokine producing T lymphocyte hybrid may be cultured in a scale of 10 - 20 ml in a conventional tissue culture medium using a Petri dish or a flask.
- a shaking culture, rotatory culture, stirred culture etc. may be carried out with or without aeration by air containing C0 2 gas.
- a mass-culture is not possible with an ordinary static culture.
- T lymphocyte-derived hybridoma which produces a lymphokine may be cultured in a large scale by employing any of (a), (b) and (c) or a combination thereof and other conditions . which generally permit the supply of adequate oxygen to the cells by enhancing the amount of oxygen dissolved in the medium.
- the T lymphocyte hybridoma requires a stimulant such as phytohemmagglutinin, concanavalin A, pokeweed mitogen, protein A, bacterial cells and components derived therefrom etc. for the production of the lymphokine
- the stimulant may be added to the medium when the proliferation of the cells has reached the predetermined cell concentration.
- the production of the lymphokine from the hybridoma may be enhanced by adding a phorbol ester, hydroxyurea, interleukin 1 etc., as required, at an appropriate concentration to the medium.
- Table 3 shows the cell proliferation in the culture modes E and F.
- the roller bottle was employed for steadily supplying fresh oxygen to the medium and rotatory culture was conducted as in F, the hybridoma exhibited favorable proliferation.
- E where culture was conducted without rotating the roller bottle, the cells did not proliferate at all.
- a commercially available ICR mouse was intraperitoneally administered with one ml of physiological saline containing 10% by weight of proteose peptone, and 4 days later, the peritoneal exudate cells were collected in conventional manner well known in the art.
- the cells were adjusted to 8 x 10 5 cells/ml and allotted 1 ml each to the respective wells on a 24-welled tissue culture plate, followed by culture for 3 'hours.
- the unattched cells were washed away with the medium to leave only the attached cells, and 1 ml of a sample to be measured for the M A F activity was added.
- the sample was removed, the well was washed once with the medium, and 100 ⁇ 1 of a suspension of P815 cells (cells generally employed in the technical field of the invention) adjusted to 2 x 10 5 cells/ml was added. After 20 hours of culture, 1 ⁇ Ci of tritium-labeled thymidine was added and culture was continued for further 4 hours, after which the cells were harvested in a conventional manner well known in the art, and the radtio- activity uptake by the P815 cells was measured. Since the attached cells activated by MAF (phagocytes) inhibit the DNA synthesis by P815, the presence of the MAF activity in the hybridoma culture supernatant may be easily judged.
- MAF phagocytes
- the obtained hybridomas were each cultured according to the method in (b) of Example 1, and each culture supernatant was collected. This culture supernatant was tested for the IFN (hereinafter sometimes referred to as IFN) activity according to the following method, to judge whether ⁇ -interferon (hereinafter sometimes referred to as ⁇ -IFN) had been spontaneously produced.
- IFN IFN
- ⁇ -IFN ⁇ -interferon
- F13-K15-I126 was cultured according to the methods C and F in (d) of Example 1, then on the third day and fourth day, each culture super-natant was collected and the produced ⁇ -IFN activity was measured according to the ⁇ -IFN activity testing method described in (c).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP166560/81 | 1981-10-19 | ||
| JP56166559A JPS5867193A (ja) | 1981-10-19 | 1981-10-19 | 免疫活性物質の製造方法 |
| JP56166560A JPS5867187A (ja) | 1981-10-19 | 1981-10-19 | 免疫活性物質の製造法 |
| JP166559/81 | 1981-10-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0077571A2 true EP0077571A2 (de) | 1983-04-27 |
| EP0077571A3 EP0077571A3 (de) | 1983-10-12 |
Family
ID=26490879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP82109658A Withdrawn EP0077571A3 (de) | 1981-10-19 | 1982-10-19 | Verfahren zur Herstellung einer Lymphokine |
Country Status (1)
| Country | Link |
|---|---|
| EP (1) | EP0077571A3 (de) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138133A1 (de) * | 1983-10-04 | 1985-04-24 | Schering Biotech Corporation | cDNA-Klone, codierend für Polypeptide mit der Wirksamkeit eines nicht-zellinienspezifischen Wachstumsfaktors (multi-CSF) und/oder Mastzellenwachstumsfaktors (MCGF) |
| EP0151844A1 (de) * | 1984-02-10 | 1985-08-21 | Hooper Trading Co. N.V. | Verfahren zur Herstellung in vitro von serumfreiem und mitogenfreiem Interleukin-2 |
| GB2170818A (en) * | 1985-02-13 | 1986-08-13 | Univ Illinois | Lymphokine containing compositions |
| WO1988006891A1 (en) * | 1987-03-11 | 1988-09-22 | Aktiebolaget Astra | Method for therapy of leukemias and certain other malignancies |
| AU603950B1 (en) * | 1988-11-30 | 1990-11-29 | Geo-Research Company, Limited | Immunity memory cell suspension and method of preparing same |
| US6420172B1 (en) | 1992-04-20 | 2002-07-16 | Tib Company, Llc | Method for inducing tumor immunity |
-
1982
- 1982-10-19 EP EP82109658A patent/EP0077571A3/de not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| THE JOURNAL OF IMMUNOLOGY, vol. 125, no. 6, December 1980, pages 2646-2653, The Williams & Wilkins Co., USA * |
| THE JOURNAL OF IMMUNOLOGY, vol. 126, no. 5, May 1981, pages 1680-1683, The Williams & Wilkins Co., USA * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138133A1 (de) * | 1983-10-04 | 1985-04-24 | Schering Biotech Corporation | cDNA-Klone, codierend für Polypeptide mit der Wirksamkeit eines nicht-zellinienspezifischen Wachstumsfaktors (multi-CSF) und/oder Mastzellenwachstumsfaktors (MCGF) |
| EP0151844A1 (de) * | 1984-02-10 | 1985-08-21 | Hooper Trading Co. N.V. | Verfahren zur Herstellung in vitro von serumfreiem und mitogenfreiem Interleukin-2 |
| GB2170818A (en) * | 1985-02-13 | 1986-08-13 | Univ Illinois | Lymphokine containing compositions |
| WO1988006891A1 (en) * | 1987-03-11 | 1988-09-22 | Aktiebolaget Astra | Method for therapy of leukemias and certain other malignancies |
| AU603950B1 (en) * | 1988-11-30 | 1990-11-29 | Geo-Research Company, Limited | Immunity memory cell suspension and method of preparing same |
| US6420172B1 (en) | 1992-04-20 | 2002-07-16 | Tib Company, Llc | Method for inducing tumor immunity |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0077571A3 (de) | 1983-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0043718B1 (de) | Zellinien | |
| US4350683A (en) | Antibody production from hybrid cell line | |
| SK25596A3 (en) | Monoclonal antibody that is able to induce apoptosis, its fragments and hybridoma | |
| EP0221748A2 (de) | Verfahren zur Herstellung von menschlichen Antikörpern | |
| Borrebaeck et al. | In vitro immunization. Effect of growth and differentiation factors on antigen-specific B cell activation and production of monoclonal antibodies to autologous antigens and weak immunogens. | |
| KR860000900B1 (ko) | 인체 황체형성 호르몬의 제조방법 | |
| EP0077571A2 (de) | Verfahren zur Herstellung einer Lymphokine | |
| KR860000895B1 (ko) | 인체 성장호르몬의 제조방법 | |
| DE3786673T2 (de) | Verfahren zur entfernung unerwünschter zellen aus menschlichen lymphozytenpopulationen, anwendung des verfahrens zur herstellung monoklonaler antikörper und dafür geeigneter kit. | |
| Letchworth | Methods for production of monoclonal antibodies | |
| EP0220045B1 (de) | Aufgebaute Zellinie | |
| KR860000896B1 (ko) | 인체프롤랙틴(Human prolactin)의 제조방법 | |
| US4316962A (en) | Novel cell line | |
| CA1215335A (en) | Tissue culture medium | |
| JPS6016590A (ja) | 免疫抑制因子を生産する突然変異体ヒトｔ細胞系統およびこのような突然変異体を得る方法 | |
| Evans et al. | Expression of Class II‐MHC Antigens by Tumor‐Associated and Peritoneal Macrophages: Systemic Induction During Tumor Growth and Tumor Rejection | |
| GB2079313A (en) | Improvements in or relating to rat myeloma cell lines | |
| SK281965B6 (sk) | Monoklonálna protilátka inhibujúca zachytávanie krvotvorných kmeňových buniek a hybridóm | |
| Greenberger et al. | Effects of murine leukemia virus infection on long-term hematopoiesis in vitro emphasized by increased survival of bone marrow cultures derived from BALB/Mo mice | |
| JPS5867187A (ja) | 免疫活性物質の製造法 | |
| SU1744107A1 (ru) | Штамм гибридных культивируемых клеток животных мUS мUSсULUS - продуцент моноклональных антител против эритроцитарного антигена V F-системы крупного рогатого скота и родственных ему видов | |
| US5250661A (en) | Established cell line | |
| JPS5867193A (ja) | 免疫活性物質の製造方法 | |
| JPH02138969A (ja) | ヒトｔ交雑細胞ライン | |
| Apte et al. | Establishment and characterization of a novel bone-marrow-derived macrophage-like accessory cell line |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): CH DE FR GB LI SE |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Designated state(s): CH DE FR GB LI SE |
|
| 17P | Request for examination filed |
Effective date: 19840313 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19870211 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAMURO, JUNJI Inventor name: YOSHIMOTO, RYOTA Inventor name: TAKATSU, KIYOSHI Inventor name: HAMAOKA, TOSHIYUKI |